EDINBURGH — A new non-invasive cancer detection test designed specifically for women is being rolled out across several health regions in the United Kingdom this month, with early recipients and clinicians describing the program as a meaningful step toward closing longstanding gaps in women’s health diagnostics. The test, developed by biomedical firm ClaraPath Diagnostics in partnership with academic researchers at the University of Glasgow, uses a combination of blood biomarker analysis and artificial intelligence-assisted imaging interpretation to screen for early-stage ovarian and endometrial cancers — two malignancies that have historically proved difficult to detect before symptoms appear and before the cancer has spread to surrounding tissue.
Ovarian cancer in particular is often described clinically as a silent disease because it rarely produces obvious or distinctive symptoms in its earliest and most treatable stages, leading to the majority of cases being diagnosed at an advanced stage. Endometrial cancer, which affects the lining of the uterus, has relatively better early-detection rates overall, but still accounts for tens of thousands of deaths annually across Europe. The combined detection test, marketed under the clinical name ClaraScreen, requires only a standard blood draw and cross-references a panel of 14 protein biomarkers against a machine-learning algorithm trained on data from more than 80,000 anonymized patient samples accumulated over a six-year development and validation period.
Among the first cohort of women to receive the new screening in Edinburgh was Margaret Dunbar, 53, a secondary school teacher who said the experience had shifted her perspective on how the health system values and prioritizes women’s well-being. “I’ve had routine smear tests for years and they are fine, but this felt different — it felt like someone was genuinely looking for things that specifically affect women,” Dunbar said after her appointment at a community health centre in the city’s Leith district. “It makes you feel like women’s health actually matters, that it isn’t an afterthought in the system.” Dunbar added that her result came back clear within four business days, and that the speed of the turnaround had itself felt reassuring compared with other diagnostic processes she had experienced.
The clinical case for the test rests on data from a phase-three trial involving 12,400 women aged 40 to 75 across five countries over a four-year follow-up period. Results published last month in the peer-reviewed journal Molecular Oncology showed ClaraScreen achieved a sensitivity of 83 percent for early-stage ovarian cancer and 79 percent for early-stage endometrial cancer, compared with sensitivity rates below 50 percent for existing opportunistic detection methods available in routine clinical practice. Specificity — the measure of the test’s ability to correctly identify those without cancer, limiting false positives that generate unnecessary further investigation — stood at 94 percent across the full trial population. Dr. Fiona McAllister, lead clinical researcher on the trial, described the figures as a genuine advance while cautioning that ClaraScreen was intended as an adjunct to, rather than a replacement for, established gynecological screening and clinical assessment.
Women’s health advocates welcomed the rollout while pressing for it to be expanded and made universally accessible without barriers related to geography or socioeconomic background. “We have seen repeatedly that when women’s health conditions are deprioritized in research funding and diagnostic investment, the consequence is women dying from cancers that could have been caught earlier,” said Alison Patel, director of the advocacy group Women’s Cancer Action Network. “ClaraScreen is encouraging progress, but the goal must be equitable access across all regions, not a postcode lottery where only some women benefit.” The UK health department confirmed that the current rollout covers six pilot regions and that an independent evaluation of evidence for coverage expansion would be conducted after 12 months of operational outcome data had been gathered.
ClaraPath Diagnostics said it was simultaneously pursuing regulatory approvals in the European Union and Canada, where it anticipated the test could be incorporated into national health programs by late 2027 if approvals proceeded on schedule. The company declined to disclose the exact cost per test to the health service but said it was working with government procurement teams to bring the unit price below 90 pounds at volume. Health economists at Northgate University estimated that if the test prevented one in eight late-stage ovarian cancer diagnoses annually in the UK alone, it would generate net savings to the health system within five years after accounting fully for the cost of the screening program itself, including follow-up investigations triggered by positive results.
The pilot program will be monitored by an independent evaluation panel, with interim findings expected in early 2027. Clinicians involved in the rollout said the broader lesson from ClaraScreen’s development was the importance of sustained, targeted investment in diagnostic research focused specifically on conditions that disproportionately or exclusively affect women — a field that researchers argued had been systematically underfunded relative to its disease burden for many decades. Eligible women in the pilot areas were being contacted directly by their registered GP practices with invitations to participate.